Clinical Trial
doi: 10.1097/00002030-200111090-00016.
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure
Affiliations
- PMID: 11684940
- DOI: 10.1097/00002030-200111090-00016
Item in Clipboard
Clinical Trial
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure
AIDS.
.
Abstract
Antiretroviral treatment interruption in 20 extensively pre-treated HIV-1 patients with treatment failure led to genotype viral reversion of at least one class of drug-mutation resistance in half of the patients. The only predictive factor of reversion was found to be the duration of interruption. The outgrowth of residual wild-type virus seems not to be a true genetic reversion because drug mutations are detected rapidly at salvage therapy re-initiation.
Similar articles
-
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.AIDS. 2005 Oct 14;19(15):1643-7. doi: 10.1097/01.aids.0000181322.17679.b2. AIDS. 2005. PMID: 16184034 Clinical Trial.
-
Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.Med Sci Monit. 2003 Apr;9(4):CS16-9. Med Sci Monit. 2003. PMID: 12709675
-
Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.Scand J Infect Dis Suppl. 2003;106:79-81. Scand J Infect Dis Suppl. 2003. PMID: 15000591 Review.
-
Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.J Virol. 2011 Jul;85(13):6403-15. doi: 10.1128/JVI.02389-10. Epub 2011 Apr 13. J Virol. 2011. PMID: 21490094 Free PMC article.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
Cited by
-
Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.Pharmacoeconomics. 2010;28 Suppl 1:17-34. doi: 10.2165/11587420-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182341 Review.
-
CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.AIDS Res Hum Retroviruses. 2008 Aug;24(8):1047-66. doi: 10.1089/aid.2008.0059. AIDS Res Hum Retroviruses. 2008. PMID: 18724805 Free PMC article.
-
Approach to the treatment-experienced patient.Curr HIV/AIDS Rep. 2005 Jun;2(2):83-9. doi: 10.1007/s11904-005-0023-5. Curr HIV/AIDS Rep. 2005. PMID: 16091253 Review.
-
Management of HIV-infected Patients with Multidrug-resistant Virus.Curr Infect Dis Rep. 2002 Jun;4(3):259-265. doi: 10.1007/s11908-002-0089-9. Curr Infect Dis Rep. 2002. PMID: 12015920
-
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148. Cochrane Database Syst Rev. 2006. PMID: 16856117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
